^
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive
:
A1
CStone Pharma Press Release - 1wk
PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
anlotinib + sintilimab
Sensitive
:
C4
Onco Targets Ther - 2wk
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive
:
A1
ISPOR 2021 - 3wk
NTRK3 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
C3
ISPOR 2021 - 3wk
NTRK2 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
C3
ISPOR 2021 - 3wk
NTRK1 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
C3
ISPOR 2021 - 3wk
NTRK3 positive
Thyroid Gland Carcinoma
larotrectinib
Sensitive
:
C3
ISPOR 2021 - 3wk
NTRK2 positive
Thyroid Gland Carcinoma
larotrectinib
Sensitive
:
C3
ISPOR 2021 - 3wk
NTRK1 positive
Thyroid Gland Carcinoma
larotrectinib
Sensitive
:
C3
ISPOR 2021 - 3wk
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
lenvatinib
Sensitive
:
A1
No biomarker
Head and Neck Cancer
cetuximab sarotalocan
Sensitive
:
A1
No biomarker
Nasopharyngeal Carcinoma
toripalimab
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive
:
A2
No biomarker
Thyroid Gland Medullary Carcinoma
dacarbazine
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our